沃森生物(300142.SZ):預計2024年度淨利潤為1.4億元-1.8億元
格隆匯1月20日丨沃森生物(300142.SZ)公佈2024年度業績預吿,2024年歸屬於上市公司股東的淨利潤盈利1.4億元–1.8億元,比上年同向下降57%-67%;扣除非經常性損益後的淨利潤盈利1.1億元–1.5億元,比上年同向下降74%-81%;營業收入收入約28.6億元。
報吿期內,公司13價肺炎球菌多糖結合疫苗繼續保持國內市場份額第一,但受國內新生兒數量下降和市場競爭加劇等因素影響,國內銷售收入較上年同期下降。報吿期內,公司加強成本費用控制,在確保必要研發投入的基礎上,結合市場環境和技術因素終止了部分項目研發工作並聚焦核心產品項目研發,報吿期內研發費用較上年同期減少約15,900萬元,公司研發投入佔營業收入的比例仍保持在20%左右。
報吿期末,公司持有已上市的開曼聖諾醫藥股份有限公司股票價格下跌及其他金融資產估值變動綜合影響,致報吿期內公允價值變動損失約9,700萬元;另外,公司對報吿期末資產進行減值測試,按企業會計準則計提相關資產減值損失約15,900萬元。
公司預計2024年非經常性損益金額約為3,200萬元,去年同期為-15,400萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.